Geode Capital Management LLC Boosts Holdings in KALA BIO, Inc. (NASDAQ:KALA)

Geode Capital Management LLC increased its stake in shares of KALA BIO, Inc. (NASDAQ:KALA) by 28.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,642 shares of the company’s stock after acquiring an additional 10,526 shares during the quarter. Geode Capital Management LLC owned about 0.78% of KALA BIO worth $331,000 at the end of the most recent quarter.

Separately, AIGH Capital Management LLC acquired a new stake in shares of KALA BIO in the fourth quarter valued at approximately $842,000. 24.61% of the stock is owned by hedge funds and other institutional investors.

KALA BIO Stock Up 0.8 %

Shares of KALA BIO stock opened at $3.75 on Friday. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.15 and a current ratio of 2.15. The firm has a fifty day moving average of $5.21 and a two-hundred day moving average of $6.47. KALA BIO, Inc. has a one year low of $2.92 and a one year high of $11.20. The company has a market cap of $24.20 million, a P/E ratio of -0.30 and a beta of -1.71.

KALA BIO (NASDAQ:KALA) last issued its earnings results on Friday, March 28th. The company reported ($1.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.28) by $0.54. On average, analysts forecast that KALA BIO, Inc. will post -10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of KALA BIO in a report on Friday, April 4th.

KALA BIO Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.